Pharma company Dr Reddy's Laboratories has raised Rs 1,077 crore debt in the current quarter to meet working capital requirements and also refinancing old loans.
In a filing to the Securities Exchange Commission, Dr Reddy's informed that one of the Company’s subsidiaries in Switzerland entered into a loan agreement with a consortium of International banks to borrow the sum of Rs 1,077.50 crore ($220 million).
"On October 20, 2011, the company, through its Swiss Subsidiary, drew down an amount of Rs 1,077.50 crore ($220 million) under its loan agreement dated September 28, 2011 with Citigroup Global Markets Asia Limited and the other Swiss Subsidiary Lenders," the company statement said.
When contacted a company spokesperson said, "the loan is being used predominantly for refinancing of short-term debt and partly for working capital requirements".
"The term of the loan is for sixty months starting from September 30, 2011," it said.
Shares of the company closed at Rs 1,588 today on the Bombay Stock Exchange up 0.40% over previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
